The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

Two companies — Eli Lilly and Novo Nordisk — dominate the weight-loss drug market and their stocks have surged in the recent ...

Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

The logic suggested by the Lilly trial is the opposite, however. It proposes that being overweight is a primary cause of ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...